Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

OTUD5

Drug and asset intelligence for OTUD5 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Recent signals(1)

ClinicalJune 25, 2026

OTUD5-SLC7A11 Axis Identified as Novel Target in AML Progression

OTUD5 promotes AML progression by stabilizing SLC7A11, suppressing ferroptosis and enhancing cell survival.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— OTUD5

Monitor ongoing research and clinical trials targeting OTUD5 or ferroptosis pathways in AML.

June 25, 2026 · N/A

Indications

Acute Myeloid Leukemia →

Therapeutic areas

Acute Myeloid Leukemia →
Oncology →
Oncology · Acute Myeloid Leukemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.